- Report
- October 2024
- 185 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- July 2024
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- March 2024
- 239 Pages
Global
From €5252EUR$5,972USD£4,350GBP
- Report
- May 2023
- 163 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- January 2021
- 201 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- June 2022
- 215 Pages
United States
From €2456EUR$2,699USD£2,106GBP
- Report
- September 2023
- 74 Pages
Global
From €3500EUR$4,120USD£3,106GBP
Menveo is a vaccine used to protect against meningococcal disease, a serious bacterial infection that can cause meningitis and sepsis. It is a quadrivalent vaccine, meaning it protects against four different types of meningococcal bacteria. Menveo is approved for use in children and adults, and is recommended for routine immunization of adolescents and young adults. It is also recommended for people at increased risk of meningococcal disease, such as those with certain medical conditions, travelers to certain countries, and military personnel.
Menveo is available in both single-dose and multi-dose vials, and is administered intramuscularly. It is manufactured by GlaxoSmithKline, and is distributed in the United States by Merck & Co. Other companies that produce meningococcal vaccines include Pfizer, Sanofi Pasteur, and Novartis. Show Less Read more
